A phase II trial is currently ongoing to investigate anti-PD-1 in combination with CIMAvax-EGF in a larger cohort of patients, including assessment of biomarkers in pre- and post-treatment tumor tissues. The gene discussed is PDCD1; the disease is neoplasm.